Lip, Gregory Y H <br/><br/>
Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a randomized dose-guiding, safety, and tolerability study of four doses of AZD0837 vs. vitamin K antagonists.  [electronic resource] 

 -  European heart journal  Dec 2009 
 - 2897-907 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1522-9645 
<br/><br/><label>Standard No.: </label>10.1093/eurheartj/ehp318  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anticoagulants--therapeutic use<br/>Antifibrinolytic Agents--therapeutic use<br/>Atrial Fibrillation--complications<br/>Biomarkers--metabolism<br/>Bleeding Time<br/>Embolism--prevention & control<br/>Female<br/>Fibrin Fibrinogen Degradation Products--metabolism<br/>Humans<br/>Male<br/>Middle Aged<br/>Stroke--prevention & control<br/>Thrombin--antagonists & inhibitors<br/>Vitamin K--antagonists & inhibitors